| No information available. |
Summary of Clinical Use  |
| A Phase 1 study, evaluating the pharmacokinetics and safety of a single intravenous dose of AVP-21D9 in healthy volunteers, has been completed (NCT01202695) [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01202695 | Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) | Phase 1 Interventional | Emergent BioSolutions | AVP-21D9 was well tolerated in healthy adult volunteers with no serious adverse events reported. | 1 |
